View as cardsView as table

Structure-based discovery of chromatin remodeling inhibitors

Fiscal Year Awarded:

2025

Principal Investigator:

Lucas Farnung

Targeting cancers by de-repressing nuclear PDC

Fiscal Year Awarded:

2025

Principal Investigator:

David Scadden

Targeting cell surface receptors for ASO delivery to bone marrow leukemia cells

Fiscal Year Awarded:

2025

Principal Investigator:

Karen Adelman

Virome screening for next generation nucleic acid delivery vectors to the lung

Fiscal Year Awarded:

2025

Principal Investigator:

George Church

Design of novel protease inhibitors to enhance immune checkpoint blockade in cancer therapy

Fiscal Year Awarded:

2024

Principal Investigator:

Mark Namchuk

Development of a synthetic promoter pipeline for safe and efficient gene therapy

Fiscal Year Awarded:

2024

Principal Investigator:

George Church

Development of novel AAV-mediated in vivo gene editing approaches to treat inherited collagen VI-related myopathies

Fiscal Year Awarded:

2024

Principal Investigator:

Amy Wagers

Functional antibody screening with micro-capsules - proof of concept with anti-EGFR

Fiscal Year Awarded:

2024

Principal Investigator:

Allon Klein

Gene editing to treat hereditary deafness

Fiscal Year Awarded:

2024

Principal Investigator:

David Corey

Identification of small molecule binders of the novel cancer immunotherapy target Bird33

Fiscal Year Awarded:

2024

Principal Investigator:

Arlene Sharpe